key: cord-0896937-y4n6jrzc authors: He, Jingyun; Hu, Peng; Gao, Yu; Zheng, Shengwei; Xu, Chao; Liu, Rongzhi; Fang, Li; Li, Ran; Han, Congyin; An, Juanjuan; Dong, Jinchun; Deng, Gang; Sun, Lei; Lv, Yunfeng title: Comparison and Application of Different Immunoassay Methods for the Detection of SARS‐CoV‐2 date: 2020-06-16 journal: J Med Virol DOI: 10.1002/jmv.26187 sha: 4cb664a894b92f9d4dafdd0497c475f2f6b70aa2 doc_id: 896937 cord_uid: y4n6jrzc The detection data of IgM and IgG antibodies in 169 patients with coronavirus disease (COVID‐19) were analyzed to evaluate differences in clinical performance between the colloidal gold method and chemiluminescence method. In this study, chemiluminescence detection of IgM antibody showed a positive conversion earlier (about 1~2 days earlier), positive conversion rates higher in different stages of disease, and a trend of declining positive rate later than colloidal gold method. For IgG antibody, the chemiluminescence method showed a positive conversion earlier and the positive rate climbing more quickly than the colloidal gold method. No obvious negative‐converting tendency of IgG detection was observed within 35 days after the onset of disease. Although colloidal gold method is generally less sensitive than chemiluminescence method, it shows advantages of shorter turn‐around time, more simple procedure and no special equipment required. The two methodologies can be chosen according to different laboratory conditions. A reasonable understanding of the performance of reagents with different methodologies can help in clinical disease diagnosis effectively and assist in the diagnosis of the progression of COVID‐19, for which the dynamic changes of antibody will provide reliable evidence. This article is protected by copyright. All rights reserved. Currently, the worldwide outbreak of coronavirus disease 2019 (COVID-19) has become a public health event of international concern (PHEIC) 1 . Effective and timely detection of novel coronavirus (SARS-CoV-2) infections will help patients to access timely treatment, prevent further transmission, and ultimately achieve effective control of the epidemic. At present, the diagnosis of SARS-CoV-2 infection mainly relies on the detection of viral nucleic acid in upper and lower respiratory tract samples [2] [3] [4] . However, due to the uneven sampling quality of the respiratory tract samples, especially upper respiratory tract samples, the different viral load of different respiratory tract samples and, at the same time, the insufficient understanding of the characteristics of the spread of SARS-CoV-2, nucleic acid tests are frequently reported as false negatives [5] [6] [7] [8] . If other clinical and laboratory diagnostic methods can be effectively combined, it will help to ensure the timely diagnosis and timely treatment of diseases [9] [10] . Serological testing, as a common method, plays an important role in the diagnosis of many pathogen infections. Moreover, the serological tests require more simple procedure and need no special equipment. The standard blood sample collection process ensures the quality of subsequent antibody detection and reduces the risk of virus transmission. With the good detection performance, serological testing can be used as supplementary diagnosis of COVID-19 suspect cases with nucleic acid negative 11 . The human body will produce specific antibodies after the virus invades. The specific IgM antibody appears first, and then the titer of IgG antibody will continue to rise. Serological tests indirectly determine whether there is a viral infection by detecting the presence and changes of specific antibody in blood samples. At present, during the COVID-19 epidemic, research on antibody production and changes in patients of COVID-19 is lack of systematization, and it is difficult to acquire clinical data of large-scale cohort studies when clinical diagnosis and treatment are in emergency condition. In the clinical trials for the purpose of pre-market registration, the SARS-CoV-2 antibody detection kits with different methodologies in China were evaluated for the clinical performance by adopting a In addition to the investigation of the multi-time-point surveillance data included in this study, the clinical trials mentioned above were also conducted to evaluate the sensitivity and specificity of the four reagents with the samples of COVID-19 confirmed cases and excluded cases. It was demonstrated that there was no cross reaction with other respiratory viruses, including other coronaviruses for these four reagents (data not shown). All the confirmed cases and excluded cases were diagnosed according to the"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia" 13 . SARS-CoV-2 IgM and IgG antibody chemiluminescence detection kits were from Maccura Biotechnology Co., Ltd. and Bioscience (Tianjin) Diagnostic Technology Co., Ltd. They finished the tests with the chemiluminescence immunoassay instruments specified in the manuals of the IVD kits; SARS-CoV-2 colloidal gold test kits came from Innovita (Tangshan) Biological Technology Co., Ltd. and Zhuhai Livzon Diagnostics Inc., of which the test process and test result interpretation did not require any test instruments. (Table 1) All the subjects included in this study were COVID-19 confirmed cases with multi-time-point surveillance data of different stage of disease. This article is protected by copyright. All rights reserved. The serum or plasma samples were collected at two or more time points of different stages of disease for each case. The stage of disease was determined according to the interval between the time of sample collection and the onset day of disease with the symptom of fever, dry cough etc., which was set as the 0 day. The time of sample collection was determined according to the needs of clinical diagnosis and treatment, but not continuous collection every day. Sample detection was done respectively referring to the instruction for use of the products. Each sample was tested for IgM and IgG simultaneously. The detection data collected in this study came from 169 COVID-19 confirmed cases, 92 males and 77 females; the age of the subjects ranged from 19 to 90 years old. The demographic information and basic characteristics of the study population are shown in Table 2 . It reveals that there is no significant difference between the basic characteristics of the chemiluminescence set, colloidal gold set, and the total set of subjects. The test results of all the cases with continuous monitoring data in the clinical trials of each product were summarized to calculate the positive rate of IgM and IgG during the disease. The production and conversion of SARS-CoV-2-specific IgM and IgG antibodies during the course of disease were observed, and the positive rates of antibodies detected by reagents with different methodologies were compared to evaluate the differences in antibody detection performance. Combining with the characteristics of different methods for clinical practice and interpretation of results, the clinical application and significance of reagents with different methodologies are discussed. Detection results of 169 COVID-19 cases using four different IVD kits (including colloidal gold method and chemiluminescence method) in seven clinical sites were recorded. Samples were collected at multiple monitoring points. A total of 2 to 11 serum or plasma samples were collected at different time points from each case. Among the 169 cases, 109 cases were detected using chemiluminescence method, and 60 cases were detected using colloidal gold method. Based on the collected data of 169 cases, analysis of positive rate at different stages of COVID-19 by reagents of colloidal gold method (60 cases) and chemiluminescence method (109 cases) was conducted, the difference in detection performance between the two methodologies are compared. This article is protected by copyright. All rights reserved. Figure 3 shows that, compared with the colloidal gold method, chemiluminescence detection of IgM antibody showed an earlier positive conversion (about 1~2 days earlier), and showed a higher positive conversion rate at different course of disease. In the 2nd to 3rd week of the disease course, the highest positive rate of IgM antibody detected by chemiluminescence method was almost 100%, and the slightly lower detection rate was observed by colloidal gold method. After the third week of disease course, the positive rate of colloidal gold method began to show a downward trend, while the positive detection rate of chemiluminescence method remained at a high level (above 80%), which tended to turn downward after the fourth week. The reason may be that the colloidal gold method has lower sensitivity than the chemiluminescence method. When the titer of the IgM antibody in patients in the early and late stages of the disease is low, some samples may Besides the sensitivity and specificity study, the continuous monitoring of SARS-CoV-2 antibody will help to understand the antibody production and conversion in COVID-19 patients and thus evaluate the importance of serological test for SARS-CoV-2 antibody in epidemic prevention and control. In this study the multi-time-point surveillance data of SARS-CoV-2 specific IgM and IgG in 169 COVID-19 confirmed cases were analyzed and the performance comparison of the colloidal gold method and chemiluminescence method in SARS-CoV-2 antibody detection was conducted. Based on the data in this study, similar to the reported outcomes of SARS-CoV-2 antibody detection, a few cases have begun to produce IgM antibodies within the first week of the disease course, but the overall positive rate is only around 50% or less. In the second week of the disease course, the IgM antibody positive rate significantly increased, and reached the peak in the third week, when more than 90% of patients showed a positive reaction. During the above process, the chemiluminescence detection reagents showed a significant advantage in sensitivity compared This article is protected by copyright. All rights reserved. with the colloidal gold method, with that the positive conversion time was advanced by 1~2 days and reached the peak positive rate earlier. Similar results were also reported in others' studies [19] [20] . The positive rate of colloidal gold IgM antibody detection shows a downward trend after three weeks, while the chemiluminescence method which have better sensitivity can still maintain a positive detection rate of more than 80%, but the overall IgM positive rate shows a significant downward trend by the end of the fourth week. The time of appearance and peak time of IgG antibody was about 2~5 days later than IgM by different test methodologies. After 23 days of disease course, the IgG antibody detections for almost all of the cases were positive. After the production, IgG antibodies can continue to be positive for at least one month and probably a much longer period. The chemiluminescence method also showed higher detection rate and earlier detection time than the colloidal gold method for SARS-CoV-2 IgG. As for other pathogens, the outcome of IgM-/ IgG-, IgM + / IgG-, IgM + / IgG +, and IgM-/ IgG + will appear in turn throughout the course of disease. At different stages of disease, different results will be obtained by detecting antibodies. Proper use of antibody detection will play a positive role in the diagnosis of SARS-CoV-2 infections and the determination of disease progression. It is worth noting that overall, the positive conversion rate obtained by multi-time-point sampling monitoring may be lower than the positive rate calculated with single-point sampling cases. The main reason is that the sampling interval of series samples from one patient is not strictly controlled. When the interval is large, the positive conversion rate in this period may be underestimated. In the diagnosis of COVID-19, positive viral nucleic acid test as direct etiological evidence is regarded as one of the key indicators. In the past few months of clinical practice and research, SARS-CoV-2 nucleic acid detection technology has proved to have a good positive detection rate, especially in the first two weeks during disease, and can effectively diagnose related viral infections. But so far, the false negatives of nucleic acid tests are still frequently reported, and the main factors include patient sampling quality, viral load and distribution, and the standardization of the detection process etc. Serological testing indirectly determines whether virus infection occurs and shows the stages of the infection by detecting the production and changes of specific antibody in the blood sample. The sampling of serum or plasma is more convenient and easier to be standardized, which is useful for dynamic monitoring of the patient's condition. The serological sample is more homogenized and proved to be highly reproducible in assays. For patients with negative nucleic acid results, serological antibody test can be used as a supplementary method to increase the positive rate of the diagnosis, help to confirm the disease state and further disease treatment and epidemic control. In the first two weeks of disease progression, IgM antibody is produced and peaked early, which is a marker of the acute phase of viral infection. In addition, the four-fold increase in IgG antibody titer can also be used as one of the judgment methods for the acute phase of infection. These This article is protected by copyright. All rights reserved. serological markers can be used as an effective supplement for nucleic acid detection and used to confirm the disease state. Two weeks later, with the effect of antiviral therapy, the positive rate of nucleic acid detection gradually decreased 6, 11 In the process of antibody detection in the clinical laboratory, chemiluminescence and colloidal gold methods have their own characteristics. Although colloidal gold method is generally less sensitive than chemiluminescence, it is fast, simple, and requires no special detection equipment. Colloidal gold method can quickly provide results for clinical use, and can be used as a POCT method. Especially for sporadic cases and emergency, colloidal gold method can provide results quickly and conveniently. According to the comparison results of this study, especially in the course of 2 to 3 weeks, the clinical detection performance of the two methodological for IgM antibody is not significantly different, and can be chosen according to laboratory conditions. Chemiluminescence method has the characteristics of automation, sensitivity, and good repeatability. It is more suitable to choose Chemiluminescence method when requiring high sample detection throughput, and auxiliary diagnosis in the early stage of the disease, especially for suspected cases with negative nucleic acid results. Chemiluminescence method has higher sensitivity to help identify cases of infection. When dynamically observing changes in antibody titer, the use of chemiluminescence method is more advantageous. Although it has been confirmed by pre-clinical and clinical studies that both colloidal gold method and chemiluminescence antibody detection reagents have relatively good specificity, it cannot completely avoid false positive results caused by cross-reactions and interference factors. Coronavirus disease (COVID-2019) situation reports Clinical features of patients infected with 2019 novel coronavirus in Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan Proposal for standardization of 2019 nCoV nucleic acid detection in clinical laboratories Accepted Article Application of the Tehnology of 2019 Novel Coronavirus Specific Antibody Detection in Serum Expert consensus on clinical application of coronavirus nucleic acid and antibody detection Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives SARS-CoV-2 specific antibody responses in COVID-19 patients Application value of chemiluminescence immunoassay in the detection of 2019-nCov antibodies 13] National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019 Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. Members of the San Matteo Pavia COVID-19 Task Force Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2) Comparative Analysis of Clinical Application Value of Four Different Detection Methods for Infectious Diseases Evaluation of the effect of electrochemiluminescence immunoassay, enzyme-linked immunosorbent assay and colloidal gold on the determination of low concentration HBsAg The authors would like to acknowledge Dr. Jie Ma from The authors declare that there is no conflict of interests.